Stock Market Reviews

PTCT (PTC Therapeutics, Inc.) News

Get the latest news, insights, and market updates on PTCT (PTC Therapeutics, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• PTC Therapeutics (PTCT) Profitability Rebound Challenges Bearish Narratives Despite Guidance for Steep Earnings Decline
  PTC Therapeutics (PTCT) has turned the corner to profitability, with earnings growing at 20.9% per year over the last five years and the company achieving positive net income in the past year. Forward guidance is less upbeat, with expectations for earnings to fall by 46% per year and revenue to decline by 2.3% per year over the next three years. Investors now find themselves weighing improved margins and a transition to profit against a forecasted dip in the near term. See our full analysis...
  Nov 6, 2025 - $PTCT
• PTC Therapeutics Inc (PTCT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
  PTC Therapeutics Inc (PTCT) reports robust third-quarter results with significant contributions from the successful launch of Safiance, despite early-stage challenges.
  Nov 5, 2025 - $PTCT
• PTC Therapeutics: Q3 Earnings Snapshot
  The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.19 per share. The biopharmaceutical company posted revenue of $211 million in the period, which also beat Street forecasts.
  Nov 4, 2025 - $PTCT
• PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates
  PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +116.81% and +20.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $PTCT
• PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
  PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025.
  Nov 4, 2025 - $PTCT
• Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics
  The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
  Nov 4, 2025 - $PTCT
• PTC Therapeutics to Participate at Upcoming Investor Conferences
  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
  Oct 31, 2025 - $PTCT
• Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates
  Travere (TVTX) delivered earnings and revenue surprises of +190.32% and +59.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Oct 30, 2025 - $PTCT
• How Recent Developments Are Shaping the PTC Therapeutics Investment Story
  PTC Therapeutics stock has recently seen a slight increase in the consensus analyst price target, moving from $66.69 to $67.93. This adjustment comes as analysts digest new regulatory and product developments, weighing both bullish momentum from successful launches as well as ongoing caution around pipeline risks. Stay tuned to find out how investors can monitor these narrative shifts as they unfold. Analyst Price Targets don't always capture the full story. Head over to our Company Report to...
  Oct 30, 2025 - $PTCT
• Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy?
  Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 29, 2025 - $PTCT